Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (11275)	10/24/2002 10:35:27 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Jim, I also agree with BJ. From furnitureman's notes: * "FDA submission is complete....Nothing else is required at the moment" * Some discussions are taking place about US labelling * Marketing Study in Canada (oral NSAIDS vs Pennsaid) was "completed at the end of Sept". "We're confident of the results" i.e that they will continue to show effigacy and safety. DMX wants results published in a journal of some kind, and to ensure that a journal will publish the results she will not pre-release before that. There they are folks right in a row in his notes and those are the three pieces we need to know what's going on with the FDA. (BTW I validate the accuracy of these quotes) Realize - The US is advertising/marketing driven The studies were conducted formally The key question EVERYONE will ask is "how is it compared to Celebreaks and Viaduck" Pennsaid is more concentrated at the location than systemic delivery Pennsaid enters the bloodstream in only trace amounts so side effects are unlikely A percentage of patients in double blinds using placebo get some serious ailments (look this up its a riot) I'll just say it. My suspicion is that Pennsaid will benefit from these trials in its ability to get better labelling and make more direct statements in both advertising and marketing. The trials being conducted by Dimethaid add real value to the ability of any major pharma (the US will be a major and its JNJ) to be successful while making a Pennsaid deal more valuable. JNJ is in all three treatment segments but in none with an NSAID and frankly Tylenol3 with codeine already owns its high end niche with no ability to cut into the NSAIDS - unless they had PenNSAID with solid head to heads. I have stopped watching for an NR for right now and am looking up herpes/shingles/and this class of ailments which knowledgable people were kind enough to clue me into regarding Pennsaid. Wolf